MedTrace Logo

Melatonin Supplementation to Improve Sleep in Patients With Heart Failure

NCT00869869 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-01-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether melatonin can improve sleep, quality of life and markers of heart failure in patients with heart failure.

Conditions

Interventions

DRUG

melatonin

2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks

DRUG

placebo

placebo

Sponsors & Collaborators

  • American Academy of Sleep Medicine

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Frank A.J.L. Scheer, Ph.D. · Brigham and Women's Hospital, Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00869869 on ClinicalTrials.gov